David Williamson, PhD, MBA

Response Rates of Esketamine Nasal Spray Plus an Oral Antidepressant Among Patients Not Meeting Study Criteria for Early Response to Treatment

Objective: Esketamine nasal spray (ESK) plus a newly initiated antidepressant (AD) reduces depression symptoms in patients with treatment-resistant depression (TRD), in a subset meeting s...

Samuel Wilkinson , MD, PhD;

Craig Nelson , MD;

Giacomo Salvadore , MD;

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Abigail Nash , MD, PhD;

Xiwu Lin , PhD;

Yevgen Tymofyeyev , PhD;

11/22/2019

Adverse Events Affecting Readiness for Discharge From the Clinical Setting After Esketamine Nasal Spray Administration

Objective: To describe clinical findings in patients considered not ready for discharge from clinical sites 2 hours after administration of esketamine nasal spray (ESK).

Leah Aluisio , PhD;

David Williamson , PhD, MBA;

Ella Daly , MB, BCh, BAO;

Michelle Han , PharmD;

Sheldon Preskorn , MD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Andrew Winokur , MD, PhD;

11/22/2019

Development of a Decision Aid in Support of Shared Decision-Making for Treatment-Resistant Depression

Shared decision-making (SDM) involves patients and clinicians choosing treatment together. SDM in mental health is hampered by lack of well-developed supporting tools. We describe an evid...

Luis Allen , MD;

Jacqueline Pesa , PhD, MPH;

Martha Rhodes ;

Alicia Shillington , PhD, MPH;

Richard Shelton , MD;

Margaret Holmes-Rovner , PhD;

David Williamson , PhD, MBA;

Phyllis Foxworth , BS;

Scott Langenecker , PhD;

11/22/2019

Predictors of Response and Remission in Patients With Treatment-Resistant Depression Treated With Esketamine

Objective: Identify patient and disease characteristics associated with greater likelihood of achieving response and remission with esketamine nasal spray (ESK) plus a newly initiated ora...

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Jack Sheehan , PhD, MBA, RPh;

Kristy Tardieu , BSN, MBA;

03/01/2019

Esketamine Nasal Spray Tolerability Trends During Post-Dose Monitoring in Patients With Treatment-Resistant Depression

Objective: This post hoc analysis assessed (1) whether the first-week incidence of adverse events (AEs) considered most commonly linked to the duration of the post-dose monitoring period ...

Mary Petrillo , PharmD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

David Williamson , PhD, MBA;

Lewis Manera , MS;

03/01/2019